|
|
|||
|
|||
|
|
|||
|
dog skin allergies |
|||
|
|
|||
|
|||
 
|
|||
|
|
|||
|
dog skin allergies DESCRIPTION Zafirlukast is a synthetic, selective peptide leukotriene receptor antagonist(LTRA), with the chemical name 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide dog skin allergies. The molecular weight of zafirlukast is 575.7 and the structural formula is:
Zafirlukast, a fine white to pale yellow amorphous powder, is practically insolublein water dog skin allergies. It is slightly soluble in methanol and freely soluble in tetrahydrofuran,dimethylsulfoxide, and acetone dog skin allergies. ACCOLATE is supplied as 10 and 20 mg tablets for oral administration dog skin allergies. Inactive Ingredients: Film-coated tablets containing croscarmellose sodium,lactose, magnesium stearate, microcrystalline cellulose, povidone, hypromellose,and titanium dioxide dog skin allergies.
In vitro studies demonstrated that zafirlukast antagonized the contractileactivity of three leukotrienes (LTC 4 , LTD 4 and LTE 4 ) in conducting airwaysmooth muscle from laboratory animals and humans dog skin allergies. Zafirlukast prevented intradermalLTD 4 -induced increases in cutaneous vascular permeability and inhibited inhaledLTD 4 -induced influx of eosinophils into animal lungs dog skin allergies. Inhalational challengestudies in sensitized sheep showed that zafirlukast suppressed the airway responsesto antigen; this included both the early- and late-phase response and the nonspecifichyperresponsiveness dog skin allergies. In humans, zafirlukast inhibited bronchoconstriction caused by several kindsof inhalational challenges dog skin allergies. Pretreatment with single oral doses of zafirlukastinhibited the bronchoconstriction caused by sulfur dioxide and cold air in patientswith asthma dog skin allergies. Pretreatment with single doses of zafirlukast attenuated the early-and late-phase reaction caused by inhalation of various antigens such as grass,cat dander, ragweed, and mixed antigens in patients with asthma dog skin allergies. Zafirlukastalso attenuated the increase in bronchial hyperresponsiveness to inhaled histaminethat followed inhaled allergen challenge dog skin allergies. Clinical Pharmacokinetics and Bioavailability: Distribution Metabolism Excretion In the pivotal bioequivalence study, the mean terminal half-life of zafirlukastis approximately 10 hours in both normal adult subjects and patients with asthma dog skin allergies. In other studies, the mean plasma half-life of zafirlukast ranged from approximately8 to 16 hours in both normal subjects and patients with asthma dog skin allergies. The pharmacokineticsof zafirlukast are approximately linear over the range from 5 mg to 80 mg dog skin allergies. Steady-stateplasma concentrations of zafirlukast are proportional to the dose and predictablefrom single-dose pharmacokinetic data dog skin allergies. Accumulation of zafirlukast in the plasmafollowing twice-daily dosing is approximately 45% dog skin allergies. The pharmacokinetic parameters of zafirlukast 20 mg administered as a singledose to 36 male volunteers are shown with the table below dog skin allergies. Mean (% Coefficient of Variation) pharmacokinetic
Race: No differences in the pharmacokinetics of zafirlukast due to race havebeen observed dog skin allergies. Elderly: The apparent oral clearance of zafirlukast decreases with age dog skin allergies. Inpatients above 65 years of age, there is an approximately 2-3 fold greater Cmax and AUC compared to young adult patients dog skin allergies. Children: Following administration of a single 20 mg dose of zafirlukast to20 boys and girls between 7 and 11 years of age, and in a second study, to 29boys and girls between 5 and 6 years of age, the following pharmacokinetic parameterswere obtained: Parameter Children age
Zafirlukast disposition was unchanged after multiple dosing (20 mg twice daily)in children and the degree of accumulation in plasma was similar to that observedin adults dog skin allergies. Hepatic Insufficiency: In a study of patients with hepatic impairment (biopsy-provencirrhosis), there was a reduced clearance of zafirlukast resulting in a 50-60%greater C max and AUC compared to normal subjects dog skin allergies. Renal Insufficiency: Based on a cross-study comparison, there are no apparentdifferences in the pharmacokinetics of zafirlukast between renally-impairedpatients and normal subjects dog skin allergies. Drug-Drug Interactions
|
|||
 
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
| ddog skin allergies doog skin allergies dogg skin allergies dog skin allergies dog sskin allergies dog skkin allergies dog skiin allergies dog skinn allergies dog skin allergies dog skin aallergies dog skin alllergies dog skin alllergies dog skin alleergies dog skin allerrgies dog skin allerggies dog skin allergiies dog skin allergiees dog skin allergiess og skin allergies dg skin allergies do skin allergies dogskin allergies dog kin allergies dog sin allergies dog skn allergies dog ski allergies dog skinallergies dog skin llergies dog skin alergies dog skin alergies dog skin allrgies dog skin allegies dog skin alleries dog skin allerges dog skin allergis dog skin allergie d og skin allergies do g skin allergies dog skin allergies dog skin allergies dog s kin allergies dog sk in allergies dog ski n allergies dog skin allergies dog skin allergies dog skin a llergies dog skin al lergies dog skin all ergies dog skin alle rgies dog skin aller gies dog skin allerg ies dog skin allergi es dog skin allergie s dog skin allergies odg skin allergies dgo skin allergies do gskin allergies dogs kin allergies dog ksin allergies dog sikn allergies dog skni allergies dog ski nallergies dog skina llergies dog skin lalergies dog skin allergies dog skin alelrgies dog skin allregies dog skin allegries dog skin alleriges dog skin allergeis dog skin allergise adog skin allergies thedog skin allergies dog skin allergies | |||
|
|
|||
|
|
|||
|
|
|||
|
Copyright 2005 D-S LTD. |
